Any current/future new fundraising through debt or equity?

Morepen Laboratories is currently evaluating various fundraising options for resource augmentation, including capacity expansion and working capital needs. The company is debt-free and has been approached by multiple banks for debt raising; discussions are ongoing but no final decisions have been made yet. Future capex plans amount to Rs. 200 to 250 Crores over the next 2-3 years across API, medical devices, and formulations divisions, which may require additional financing. The financial team is working on finalizing plans, and the company is open to debt or equity fundraising depending on

Any current/future capex/capital investment/strategic investment?

Capex plans span across API, medical devices, and formulations. API segment capex planned around Rs.125 Crores. Medical devices capex estimated at Rs.50 Crores. Formulation capex roughly Rs.40 Crores. Total capex plus working capital in next 2-3 years expected between Rs.200 Crores to Rs.250 Crores. Current capacity expansions funded from internal accruals (e.g., Rs.50 Crores spent in last 9 months). Additional API capacity planned: 250 KL within next 12 months. Working capital augmentation planned due to 20-25% expected growth. Company is debt-free but open to debt raising and evaluating mult

Future growth expectations in sales/revenue/volumes?

Morepen Laboratories targets a steady growth rate in revenue and volumes. API segment expected to grow at a CAGR of 17%-18%, potentially up to 20%-25% with capacity expansions. Medical devices showing strong growth, around 24% quarterly and 37% over nine months, with plans to increase distribution. Formulation business is a new growth driver, having grown 40% in the recent quarter, expected to double to around Rs.500 Crores in three years. Dr. Morepen OTC brand currently flat/fluctuating due to limited marketing investments but new innovative products are planned for launch. Overall growth tar

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins are expected to rise by 150 to 200 basis points annually over the next few years, moving from around 12% to potentially double digits by FY2026. Profit After Tax (PAT) is anticipated to increase from about 6% to 8-10% by FY2026, reflecting steady margin improvement. EPS for the current year is around Rs.2+ if the current quarter's performance sustains, indicating strong growth prospects. Revenue growth is targeted at 16-17% for the current year with aspirations to reach 20-25% CAGR in the next 2-3 years. Operating margins (EBITDA) are expected to stabilize in early double digits

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details on the current or expected order book or pending orders for Morepen Laboratories Limited. However, the company mentions: - Strong growth and increasing production, with a 37%-40% increase in quantity produced over nine months. - Capacity utilization is high (90%-95% in API, peak levels in devices and formulations). - Ongoing capacity expansions and investments in API, medical devices, and formulations to support growth. - Capex plans of Rs. 200-250 Crores over 2-3 years indicating preparation for increased orders. No specific figures on

Morepen Laboratories LtdQ3 FY24Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119P/E: 56.2Market Cap: ₹6.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 3

Morepen Laboratories targets a steady growth rate in revenue and volumes.
API segment expected to grow at a CAGR of 17%-18%, potentially up to 20%-25% with capacity expansions.
Medical devices showing strong growth, around 24% quarterly and 37% over nine months, with plans to increase distribution.
Formulation business is a new growth driver, having grown 40% in the recent quarter, expected to double to around Rs.500 Crores in three years.
Dr. Morepen OTC brand currently flat/fluctuating due to limited marketing investments but new innovative products are planned for launch.
Overall growth target ranges from 20%-25% annually.
Capacity expansions underway: Rs.125-150 Crores in API, Rs.50 Crores in medical devices, Rs.40 Crores in formulations.
Focus on internal accruals for funding, with fundraising plans under evaluation.
Aim to maintain and improve EBITDA and PAT margins with operational efficiencies and product mix improvements.

Margin guidance

Category 1

EBITDA margins are expected to rise by 150 to 200 basis points annually over the next few years, moving from around 12% to potentially double digits by FY2026.
Profit After Tax (PAT) is anticipated to increase from about 6% to 8-10% by FY2026, reflecting steady margin improvement.
EPS for the current year is around Rs.2+ if the current quarter's performance sustains, indicating strong growth prospects.
Revenue growth is targeted at 16-17% for the current year with aspirations to reach 20-25% CAGR in the next 2-3 years.
Operating margins (EBITDA) are expected to stabilize in early double digits, contributing positively to bottom-line growth.
The company is focusing on capacity expansion and new product launches to fuel future profit and earnings growth.
Working capital and capex needs may prompt resource augmentation, but the firm remains debt-free and open to financing options.

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Morepen Laboratories is currently evaluating various fundraising options for resource augmentation, including capacity expansion and working capital needs.
The company is debt-free and has been approached by multiple banks for debt raising; discussions are ongoing but no final decisions have been made yet.
Future capex plans amount to Rs. 200 to 250 Crores over the next 2-3 years across API, medical devices, and formulations divisions, which may require additional financing.
The financial team is working on finalizing plans, and the company is open to debt or equity fundraising depending on market conditions and performance.
No specific details or timelines about new fundraising through debt or equity have been disclosed yet; the company is at an evaluation stage.

Order book

Yes

The transcript does not provide explicit details on the current or expected order book or pending orders for Morepen Laboratories Limited.
However, the company mentions:
- Strong growth and increasing production, with a 37%-40% increase in quantity produced over nine months.
- Capacity utilization is high (90%-95% in API, peak levels in devices and formulations).
- Ongoing capacity expansions and investments in API, medical devices, and formulations to support growth.
- Capex plans of Rs. 200-250 Crores over 2-3 years indicating preparation for increased orders.
No specific figures on outstanding or pending orders are discussed during the call.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex plans span across API, medical devices, and formulations.
API segment capex planned around Rs.125 Crores.
Medical devices capex estimated at Rs.50 Crores.
Formulation capex roughly Rs.40 Crores.
Total capex plus working capital in next 2-3 years expected between Rs.200 Crores to Rs.250 Crores.
Current capacity expansions funded from internal accruals (e.g., Rs.50 Crores spent in last 9 months).
Additional API capacity planned: 250 KL within next 12 months.
Working capital augmentation planned due to 20-25% expected growth.
Company is debt-free but open to debt raising and evaluating multiple financing options.
No final fundraising decisions yet; resource augmentation and capacity building are under evaluation.
Focus on zero liquid discharge (ZLD) plant approval for environmental compliance.

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 3Mar 1

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →